zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
Company profile
Ticker
ZLAB
Exchange
Website
CEO
Ying Samantha Du
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Zai Lab (Hong Kong) Limited • Zai Lab (Shanghai) Co., Ltd. • Zai Lab International • Zai Lab (Suzhou) Co., Ltd. • Zai Lab Trading (Suzhou) Co., Ltd. • Zai Biopharmaceutical (Suzhou) Co., Ltd • Zai Lab (Aust) Pty., Ltd. • Zai Lab (US) LLC • ZLIP Holding Limited • ZL Capital Limited ...
ZLAB stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
19 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Zai Lab Announces Full-Year 2023
27 Feb 24
8-K
Entry into a Material Definitive Agreement
8 Feb 24
10-K/A
2022 FY
Annual report (amended)
22 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Zai Lab Announces Third Quarter 2023
7 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Zai Lab Announces Second Quarter 2023
7 Aug 23
Transcripts
ZLAB
Earnings call transcript
2023 Q3
8 Nov 23
ZLAB
Earnings call transcript
2023 Q2
8 Aug 23
ZLAB
Earnings call transcript
2023 Q2
8 Aug 23
ZLAB
Earnings call transcript
2023 Q1
10 May 23
ZLAB
Earnings call transcript
2023 Q1
10 May 23
ZLAB
Earnings call transcript
2022 Q4
2 Mar 23
ZLAB
Earnings call transcript
2022 Q4
2 Mar 23
ZLAB
Earnings call transcript
2022 Q3
10 Nov 22
ZLAB
Earnings call transcript
2022 Q3
10 Nov 22
ZLAB
Earnings call transcript
2022 Q2
10 Aug 22
Latest ownership filings
4
Joshua L Smiley
5 Apr 24
4
Harald Reinhart
5 Apr 24
4
Frazor Titus Edmondson III
5 Apr 24
4
Ying Du
5 Apr 24
4
Yajing Chen
5 Apr 24
4
Rafael Amado
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 790.60 mm | 790.60 mm | 790.60 mm | 790.60 mm | 790.60 mm | 790.60 mm |
Cash burn (monthly) | 23.45 mm | 27.47 mm | 27.86 mm | 28.32 mm | 18.42 mm | 24.38 mm |
Cash used (since last report) | 161.47 mm | 189.18 mm | 191.82 mm | 195.03 mm | 126.87 mm | 167.87 mm |
Cash remaining | 629.13 mm | 601.42 mm | 598.78 mm | 595.56 mm | 663.73 mm | 622.72 mm |
Runway (months of cash) | 26.8 | 21.9 | 21.5 | 21.0 | 36.0 | 25.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 119 |
Opened positions | 12 |
Closed positions | 29 |
Increased positions | 39 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 952.44 bn |
Total shares | 140.83 mm |
Total puts | 65.70 k |
Total calls | 9.60 k |
Total put/call ratio | 6.8 |
Largest owners | Shares | Value |
---|---|---|
Qiming Venture Partners IV | 79.23 mm | $0.00 |
Advantech Capital | 22.23 mm | $3.01 bn |
Capital World Investors | 5.22 mm | $126.87 bn |
JHG Janus Henderson | 4.24 mm | $103.15 bn |
IVZ Invesco | 3.21 mm | $78.02 bn |
T. Rowe Price | 2.72 mm | $66.14 bn |
Viking Global Investors | 2.49 mm | $60.56 bn |
Wellington Management | 1.92 mm | $46.74 bn |
Segantii Capital Management | 1.79 mm | $43.26 bn |
Bamco | 1.58 mm | $38.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Apr 24 | Amado Rafael | American Depositary Shares | Sell | Dispose S | No | No | 15.673 | 1,952 | 30.59 k | 23,532 |
4 Apr 24 | Yajing Chen | American Depositary Shares | Sell | Dispose S | No | No | 15.673 | 845 | 13.24 k | 9,618 |
4 Apr 24 | Joshua L Smiley | American Depositary Shares | Sell | Dispose S | No | No | 15.673 | 1,988 | 31.16 k | 28,684 |
4 Apr 24 | Harald Reinhart | American Depositary Shares | Sell | Dispose S | No | No | 15.673 | 2,105 | 32.99 k | 51,800 |
3 Apr 24 | Amado Rafael | American Depositary Shares | Option exercise | Acquire M | No | No | 15.9 | 5,391 | 85.72 k | 25,484 |
3 Apr 24 | Amado Rafael | Restricted Share Units American Depositary Shares | Option exercise | Dispose M | No | No | 0 | 5,391 | 0.00 | 16,173 |
3 Apr 24 | Du Ying | Restricted Share Units American Depositary Shares | Grant | Acquire A | No | No | 0 | 27,000 | 0.00 | 27,000 |
3 Apr 24 | Du Ying | Stock Options American Depositary Shares | Grant | Acquire A | No | No | 16.18 | 533,065 | 8.62 mm | 533,065 |
3 Apr 24 | Yajing Chen | American Depositary Shares | Option exercise | Acquire M | No | No | 15.9 | 2,500 | 39.75 k | 10,463 |
3 Apr 24 | Yajing Chen | Restricted Share Units American Depositary Shares | Option exercise | Dispose M | No | No | 0 | 2,500 | 0.00 | 7,500 |
News
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
1 Apr 24
Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Extension In Time To Intracranial Progression For Patients With Brain Metastases From Non-Small Cell Lung Cancer
27 Mar 24
Stock Disconnect Triggers Investor Exodus From CStone Pharma
14 Mar 24
Zai Lab To Present Findings From Preclinical Studies Highlighting ZL-1310, A Novel Antibody-Drug Conjugate (ADC) For Treatment Of Solid Tumors
14 Mar 24
Zai Lab To Present Final Overall Survival DataFfrom Phase 3 NORA Study of ZEJULA In Platinum-Sensitive Recurrent Ovarian Cancer
6 Mar 24
Press releases
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
15 Apr 24
Zai Lab Statement on Executive Management Team's Agreement on Share Activities
11 Apr 24
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
2 Apr 24
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
27 Mar 24
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
13 Mar 24